TL;DR
This study investigated whether a specialized infant formula, partially hydrolyzed whey with added prebiotics (pHF-OS), could prevent eczema in high-risk infants. The large, multicenter randomized controlled trial found no significant difference in eczema incidence between infants fed pHF-OS and those fed standard cow's milk formula. While no eczema prevention was observed, the study did note some interesting immunological changes in infants fed the specialized formula, suggesting potential immune modulation effects that warrant further investigation.
What Problem Does This Paper Address?
Eczema, particularly in infants, is a common and often distressing condition with significant implications for infant health and family well-being. For infants at high risk of developing allergic diseases (due to a family history of allergies), current guidelines often recommend the use of hydrolyzed infant formulas if formula feeding is introduced before six months of age. However, the evidence supporting this recommendation has been mixed. Furthermore, there's growing interest in the role of prebiotics – non-digestible food ingredients that selectively stimulate the growth and/or activity of beneficial bacteria in the gut – in modulating the immune system and potentially preventing allergic conditions. This paper addresses the question of whether combining these two approaches – a partially hydrolyzed whey formula with added prebiotics (pHF-OS) – could offer a more effective strategy for preventing eczema in high-risk infants compared to standard formula.
Methods
This was a large, multicenter, randomized, double-blind, controlled trial. High-risk infants (defined by parental history of allergic disease) were recruited from specialist pediatric centers across Australia, Singapore, the UK, and Ireland. Infants were randomized to receive either the active formula (pHF-OS) or a standard cow's milk formula. The study design was parallel-group, meaning participants stayed in their assigned group throughout the study. Blinding was maintained for participants, outcome assessors, and researchers to prevent bias.
Key methodological aspects include:
- Randomization: A computer-generated sequence was used, stratified by study center and parental allergic history, to ensure balanced groups.
- Blinding: Both the active and control formulas were presented in identical, coded tins, and the code was only broken after all analyses were completed.
- Primary Outcome: The cumulative incidence of eczema by 12 months of age in infants who started formula before 4 weeks of age (the "early introduction subgroup").
- Secondary Outcomes: Included cumulative eczema incidence by 12 or 18 months in all randomized infants, immune markers at 6 months, and adverse events.
- Immune Assessment: This involved measuring serum immunoglobulin levels (total IgE, cow's milk-specific IgE, hen's egg-specific IgE, and IgG1) and analyzing peripheral blood mononuclear cells (PBMCs) for plasmacytoid dendritic cell (pDC) and regulatory T-cell (Treg) populations, as well as cytokine production.
Datasets
The study utilized data collected from 1047 infants enrolled in the trial. Participant characteristics were collected at baseline, and follow-up data on eczema incidence, immune markers, and adverse events were collected at various time points up to 18 months of age. No new public datasets were introduced; the study relied on data collected directly from the trial participants.
Key Insights and Ideas
- No Eczema Prevention: The most significant finding is the lack of evidence that pHF-OS prevents eczema in high-risk infants within the first year of life. This challenges the hypothesis that this combined approach would be more effective than standard formula.
- Immune Modulation: Despite the lack of clinical benefit for eczema, the study observed interesting immunological changes. Infants fed pHF-OS showed significantly lower levels of cow's milk-specific IgG1 and increased percentages of regulatory T-cells (Tregs) and plasmacytoid dendritic cells (pDCs).
- Potential Biomarker: The reduced cow's milk-specific IgG1 in the active group is particularly noteworthy. Early food-specific IgG1 has been suggested as a potential biomarker for future allergic disease development, and its reduction might indicate a hypo-allergenic effect of the formula, even if it didn't translate to eczema prevention.
- Treg and pDC Role: The increase in Tregs and pDCs in the intervention group supports the idea that dietary exposures can influence immune development. These cells are known to play roles in immune tolerance and regulation, suggesting a potential for immune modulation.
- Hydrolysis vs. Prebiotics: The study's design, combining both hydrolyzed formula and prebiotics, makes it difficult to disentangle the specific effects of each component. This complexity is a limitation but also highlights the need for future research to isolate these effects.
Key Results
- Eczema Incidence: By 12 months, eczema occurred in 28.7% of infants in the pHF-OS group and 28.7% in the control group (OR 0.98, 95% CI 0.68–1.40; P = 0.90) in the early introduction subgroup. Similar results were observed for all randomized infants and at 18 months.
- Immune Markers:
- Total and specific IgE levels did not differ between groups.
- Cow's milk-specific IgG1 was significantly lower in the active group (median 33.1 AU vs. 825.8 AU; P < 0.0001).
- Treg percentages were increased in the active group in unstimulated (P = 0.03) and TT-stimulated (P = 0.03) cultures.
- pDC percentages were increased in the active group in unstimulated (P = 0.006) and TT-stimulated (P = 0.02) PBMCs.
- Adverse Events: There were no significant differences in the number of infants experiencing adverse events or serious adverse events between the active and control groups.
Limitations and Future Work
The authors acknowledge several limitations:
- Combined Intervention: It's impossible to determine whether the lack of eczema prevention was due to the hydrolyzed formula, the prebiotics, or their interaction. Future studies should ideally investigate these components separately.
- Small PBMC Subgroup: The immune analyses were performed on a subset of infants, and findings should be interpreted cautiously, especially as multiple comparisons were made without formal adjustment.
- Cryopreservation: The use of cryopreserved PBMCs for analysis might influence cell phenotype and function.
- Generalizability: The findings may not be generalizable to infants without a family history of allergic disease or those who do not use cow's milk-based infant formula within the first 18 weeks of life.
The authors suggest that future research should focus on confirming the observed immunological changes in a separate cohort. They also propose that the concept of "hypo-allergenicity" in infant formula needs re-evaluation, given the growing understanding of eczema as a skin barrier defect. Further studies are needed to confirm the immune findings and establish their relevance to longer-term health implications, such as asthma and allergic rhinitis.
Summary updated